ScreenerHero

KNSAKiniksa Pharmaceuticals, Ltd.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · kiniksa.com
79.03USDMkt Cap: 6.08B $P/E: 79.83

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interl…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
HIK
Hikma Pharmaceuticals PLC
$4.35BUSDP/E 12.7

Key Statistics

Company
Market Cap6.08B $
Enterprise Value5.61B $
Revenue (TTM)840.85M $
Gross Profit370.35M $
Net Income (TTM)59.01M $
Revenue/Share11.03 USD
Last Price79.03 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees366
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)79.83
P/E (Forward)48.51
PEG—
EV/EBITDA54.94
EV/Revenue6.67
P/S7.28
P/B9.35
EPS (TTM)0.96
EPS (Forward)1.62
52W Range
78.0153% of range79.93
52W High79.93 USD
52W Low78.01 USD
Profitability
Gross Margin54.66%
Oper. Margin11.16%
EBITDA Margin12.14%
Profit Margin8.71%
ROE10.40%
ROA7.73%
Growth
Revenue Growth55.40%
Earnings Growth30.40%
Cash Flow & Leverage
Operating CF137.99M $
CapEx (TTM)1.57M $
FCF Margin15.00%
FCF Yield2.07%
Net Debt-517.03M $
Net Debt/EBITDA-5.07
Balance Sheet
Debt/Equity0.02
Current Ratio3.90
Quick Ratio3.21
Book Value/Sh8.389 USD
Cash/Share6.741 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)98.00 USD
Upside (mean)+24.0%
Target Range87.00 USD – 108.00 USD
$87.00+24.0% to mean$108.00
# Analysts8
Ownership
Shares Out.46.30M
Float40.19M
Insiders3.49%
Institutions100.79%
Short Interest
Short Ratio5.3d
Short % Float10.80%
Short % Out.5.53%
Shares Short4.32M
Short (prev mo.)4.15M
Technical
SMA 5065.84 (+20.0%)
SMA 20050.49 (+56.5%)
Beta0.09
S&P 52W Chg21.00%
Avg Vol (30d)260.69K
Avg Vol (10d)413.93K
Technical Indicators
RSI (14)62.5
MACD3.6585
MACD Signal3.9987
MACD Hist.-0.3403
BB Upper84.45 USD
BB Middle77.03 USD
BB Lower69.60 USD
BB Width19.28%
ATR (14)2.908 USD
Vol Ratio (20d)0.36x